Usefulness of vonoprazan,a potassium ion-competitive acid blocker,for primary eradication of Helicobacter pylori

被引:8
|
作者
Shinya Yamada [1 ]
Takumi Kawakami [1 ]
Yoshikazu Nakatsugawa [1 ]
Takahiro Suzuki [1 ]
Hideki Fujii [1 ]
Naoya Tomatsuri [1 ]
Hideki Nakamura [1 ]
Hideki Sato [1 ]
Yusuke Okuyama [1 ]
Hiroyuki Kimura [1 ]
Norimasa Yoshida [1 ]
机构
[1] Department of Gastroenterology,Japanese Red Cross Kyoto Daiichi Hospital
关键词
Helicobacter pylori; Eradication; Vonoprazan; Chronic gastritis; Potassium ion-competitive acid blocker;
D O I
暂无
中图分类号
R573 [胃疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM To investigate usefulness of triple therapy with vonoprazan,a potassium ion-competitive acid blocker and antibiotics,for Helicobacter pylori(H.pylori) eradication.METHODS The H.pylori eradication rate was examined in 2507 patients(2055 undergoing primary eradication and 452 undergoing secondary eradication,excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015.For patients treated from March 2013 to February 2015,a proton pump inhibitor(PPI) was used to reduce acid secretion,while vonoprazan was used after March 2015.The success rates of the 2 regimens(PPI + amoxicillin + clarithromycin/metronidazole,or vonoprazan + amoxicillin + clarithromycin/metronidazole) were compared.RESULTS The success rate of primary H.pylori eradication was significantly higher in the vonoprazan group.When stratified by the underlying disease,a significant increase of the H.pylori eradication rate was observed in patients with chronic gastritis.A significantly lower H.pylori eradication rate was observed in younger patients compared to older patients in the PPI group,but there was no difference according to age in the vonoprazan group.On the otherhand,the success rate of secondary eradication was similar at approximately 90% in both groups.CONCLUSION Vonoprazan is very useful for primary eradication of H.pylori,and may become a first-line acid secretion inhibitor instead of PPIs.
引用
收藏
页码:550 / 555
页数:6
相关论文
共 50 条
  • [1] Usefulness and safety of vonoprazan, a potassium ion-competitive acid blocker, for Helicobacter pylori eradication of elderly patients
    Hayashi, Yasuyo
    Sadamoto, Yojiro
    Esaki, Mitsuru
    Bussaka, Kouta
    Itonaga, Shuichi
    Yokoyama, Azusa
    Hosokawa, Taizou
    Tanaka, Yoshimasa
    Mizutani, Takahiro
    Akiho, Hirotada
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 73 - 74
  • [2] The cost effectiveness of vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy
    Hosokawa, Takanori
    Kaminishi, Michio
    Nouchi, Toshihiko
    Takeda, Yuichi
    Kojima, Shigeru
    Ono, Keichi
    Uraushihara, Koji
    Yamadi, Osamu
    Suzuki, Shoko
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 62 - 62
  • [3] Eradication of Helicobacter pylori by a potassium-competitive acid blocker alone?
    Waldum, Helge
    Fossmark, Reidar
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2025, 60 (01) : 10 - 12
  • [4] EVALUATION OF THE EFFICACY AND SAFETY OF HELICOBACTOR PYLORI ERADICATION WITH VONOPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER
    Nishie, Hirotada
    Ozeki, Keiji
    Kataoka, Hiromi
    Ichikawa, Hiroshi
    Nojiri, Yu
    Inagaki, Yusuke
    Nomura, Satoshi
    Hayashi, Noriyuki
    Katano, Takahito
    Okamoto, Yasuyuki
    Mizoshita, Tsutomu
    Shimura, Takaya
    Mori, Yoshinori
    Kubota, Eiji
    Tanida, Satoshi
    Joh, Takashi
    GASTROENTEROLOGY, 2017, 152 (05) : S246 - S247
  • [5] Usefulness of Helicobacter pylori Eradication Therapy with a PPI (or Potassium-competitive Acid Blocker), Metronidazole, and Sitafloxacin in Patients with Penicillin Allergy
    Tanaka, Akifumi
    Tokunaga, Kengo
    Takahashi, Shin'ichi
    Mori, Hideaki
    Hisamatsu, Tadakazu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S1289 - S1289
  • [6] Vonoprazan for Helicobacter pylori eradication
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (02): : 93 - 93
  • [7] Efficacy of Sitafloxacin-Based Triple Therapy for Eradication-Refractory Helicobacter Pylori and Salvage Therapy With the New Potassium-Competitive Acid Blocker Vonoprazan
    Okimoto, Kenichiro
    Arai, Makoto
    Kasamatsu, Shingo
    Ishigami, Hideaki
    Saito, Keiko
    Maruoka, Daisuke
    Matsumura, Tomoaki
    Nakagawa, Tomoo
    Katsuno, Tatsuro
    Yokosuka, Osamu
    GASTROENTEROLOGY, 2016, 150 (04) : S447 - S447
  • [8] Usefulness of vonoprazan-based triple therapy for eradication of Helicobacter pylori
    Sato, Yuki
    Takenaka, Ryuta
    Kawai, Daisuke
    Takemoto, Kouji
    Tsugeno, Hirofumi
    Fujiki, Shigeatsu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 74 - 75
  • [9] Vonoprazan: A New Potassium-Competitive Acid Blocker
    Onge, Erin St.
    Phillips, Bradley
    JOURNAL OF PHARMACY TECHNOLOGY, 2023, 39 (03) : 139 - 146
  • [10] Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
    Sue, Soichiro
    Maeda, Shin
    GUT AND LIVER, 2021, 15 (06) : 799 - 810